MOSCOW (Sputnik) – The Oxford/AstraZeneca coronavirus vaccine solely gives restricted safety towards the South African pressure of the coronavirus, a research on account of be launched on Monday exhibits.
“A two-dose regimen of [the vaccine] did not show protection against mild-moderate Covid-19 due to [the South African variant]”, the research says, as quoted by The Financial Times.
“We do believe our vaccine could protect against severe disease, as neutralizing antibody activity is equivalent to that of other Covid-19 vaccines that have demonstrated activity against more severe disease, particularly when the dosing interval is optimised to 8-12 weeks,” an AstraZeneca spokesperson mentioned as quoted by The Financial Times, including that different immune responses, resembling T-cells, “may remain intact” towards the South African variant.
According to the spokesperson, AstraZeneca has already began adapting its vaccine to the South African pressure, in order that it’s prepared for fall deliveries, if wanted.
Earlier this month, the University of Oxford mentioned that the AstraZeneca vaccine had confirmed its effectiveness towards the UK coronavirus variant.